Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE®
Data support AGAMREE®’s potential use as a treatment across a broad range of chronic inflammatory rare diseases
A Digital Publication for the Practicing Medical Specialist, Industry Executive, & Investor
Data support AGAMREE®’s potential use as a treatment across a broad range of chronic inflammatory rare diseases